Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of Leramistat in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05951296 is registered in ClinicalTrials.gov with Modern Biosciences Ltd as lead sponsor.

NCT NCT05951296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05951296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of Leramistat in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Lead sponsor
Modern Biosciences Ltd
Phase
Phase 2
Overall status
Withdrawn
Start date
August 30, 2023
Completion date
March 14, 2024
Enrollment
0 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis